Rapid test for malaria
This article was originally published in The Gray Sheet
Executive Summary
Inverness Medical Innovations' BinaxNOW becomes the first rapid test for malaria cleared by FDA June 26. Test results, which are produced 15 minutes after placing a few drops of blood on a dipstick, are 95% accurate and must be confirmed with standard microscopic evaluation, FDA says. BinaxNOW has been marketed outside the United States, where other rapid tests for malaria are available, for nearly seven years. Each year, U.S. cases of malaria number between 1,000 and 1,500, according to Inverness, while 300 million to 500 million people contract the disease worldwide...
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.